Spero Therapeutics (SPRO) Operating Income (QoQ) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -124.00% |
| Dec 31, 2025 | 496.73% |
| Sep 30, 2025 | -223.90% |
| Jun 30, 2025 | 83.41% |
| Mar 31, 2025 | 41.99% |
| Dec 31, 2024 | -36.57% |
| Sep 30, 2024 | 2.46% |
| Jun 30, 2024 | -36.33% |
| Mar 31, 2024 | -125.68% |
| Dec 31, 2023 | 2,915.67% |
| Sep 30, 2023 | 85.00% |
| Jun 30, 2023 | 9.40% |
| Mar 31, 2023 | -153.14% |
| Dec 31, 2022 | 329.30% |
| Sep 30, 2022 | 55.23% |
| Jun 30, 2022 | 13.66% |
| Mar 31, 2022 | -9.84% |
| Dec 31, 2021 | -22.10% |
| Sep 30, 2021 | -21.48% |
| Jun 30, 2021 | 4.44% |
| Mar 31, 2021 | -3.23% |
| Dec 31, 2020 | 1.18% |
| Sep 30, 2020 | -2.94% |
| Jun 30, 2020 | 19.04% |
| Mar 31, 2020 | 11.83% |
| Dec 31, 2019 | -43.91% |
| Sep 30, 2019 | -31.74% |
| Jun 30, 2019 | -139.68% |
| Mar 31, 2019 | 48.61% |
| Dec 31, 2018 | -1.36% |
| Sep 30, 2018 | -9.67% |
| Jun 30, 2018 | 7.81% |
| Mar 31, 2018 | 22.74% |
| Dec 31, 2017 | -40.48% |
| Sep 30, 2017 | 1.96% |
| Jun 30, 2017 | -33.77% |
| Mar 31, 2017 | 13.75% |
| Dec 31, 2016 | -11.32% |